Stockscreener 앱 받기
14.67
0.48%
0.07
시간 외 거래:
14.65
-0.02
-0.14%
전일 마감가:
$14.60
열려 있는:
$14.47
하루 거래량:
176.81K
Relative Volume:
1.02
시가총액:
$994.15M
수익:
$-9,000
순이익/손실:
$-68.03M
주가수익비율:
-13.97
EPS:
-1.05
순현금흐름:
$-44.76M
1주 성능:
+7.08%
1개월 성능:
+10.55%
6개월 성능:
-4.12%
1년 성능:
-23.39%
1일 변동 폭
$14.45
$15.05
1주일 범위
$13.17
$15.05
52주 변동 폭
$12.56
$25.00
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
PLSE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
14.67 | 989.41M | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
592.85 | 200.78B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.36 | 56.69B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
81.81 | 39.62B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
249.19 | 35.81B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
39.77 | 30.70B | 27.43B | 1.27B | 1.01B | 1.5829 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium - Bluefield Daily Telegraph
(PLSE) Volatility Zones as Tactical Triggers - Stock Traders Daily
What analysts say about Pulse Biosciences Inc 6L8 stockEarnings Growth Projections & Test Our Stock Screener — Free Forever - earlytimes.in
Chipmakers Recap: How Pulse Biosciences Inc 6L8 stock responds to bond market - moha.gov.vn
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
Total debt per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Positron (OTCMKTS:POSC) vs. Pulse Biosciences (NASDAQ:PLSE) Critical Comparison - Defense World
What drives Pulse Biosciences Inc 6L8 stock priceHigh Dividend Yield Stocks & High Profit Market Growth - earlytimes.in
MSN Money - MSN
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial - Sahm
Pulse Biosciences Updates Investors on Product Advancements - MSN
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial - Sahm
Pulse Biosciences holds 2025 annual stockholder meeting - MSN
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans - Sahm
Can Pulse Biosciences Inc. stock beat market expectations this quarterEarnings Recap Report & Growth Focused Stock Reports - Улправда
Forecast Cut: Will Pulse Biosciences Inc. stock outperform tech sector in 2025July 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
What technical signals suggest for Pulse Biosciences Inc. stockSell Signal & AI Driven Price Forecasts - Улправда
How buybacks impact Pulse Biosciences Inc. stock valueEarnings Growth Summary & Long-Term Capital Growth Strategies - Улправда
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Market Pulse: How Aura Biosciences Inc. stock performs in high volatility marketsWall Street Watch & Long-Term Safe Investment Ideas - Улправда
Aug Fed Impact: Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - Улправда
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial - sharewise.com
How Pulse Biosciences Inc. stock responds to policy changesMarket Risk Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Can Pulse Biosciences Inc. stock resist market sell offs2025 Support & Resistance & Community Verified Trade Signals - DonanımHaber
FDA approves Pulse Biosciences’ atrial fibrillation trial By Investing.com - Investing.com Australia
How Pulse Biosciences Inc. stock benefits from tech adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - DonanımHaber
Short Covering: Can Pulse Biosciences Inc. stock beat market expectations this quarter2025 Top Decliners & Long-Term Growth Plans - Улправда
Pulse Biosciences wins FDA approval to begin PFA catheter study - MedTech Dive
Can Pulse Biosciences Inc. (6L8) stock deliver double digit returns2025 Year in Review & Smart Investment Allocation Insights - ulpravda.ru
Pulse Biosciences gains FDA IDE for NANOPULSE-AF trial - TipRanks
Pulse Biosciences IDE Approval for Atrial Fibrillation Study - TradingView — Track All Markets
[8-K] PULSE BIOSCIENCES, INC. Reports Material Event | PLSE SEC FilingForm 8-K - Stock Titan
Pulse Biosciences Receives FDA Approval to Launch Cardiac Catheter Ablation Study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation - Investing News Network
FDA approves Pulse Biosciences’ atrial fibrillation trial - Investing.com
Pulse Biosciences announces FDA IDE approval to initiate its nPulse cardiac catheter ablation system study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study - TradingView — Track All Markets
Will Pulse Biosciences Inc. stock outperform tech sector in 2025Market Performance Recap & Scalable Portfolio Growth Ideas - Улправда
Pulse Biosciences Earnings Notes - Trefis
How (PLSE) Movements Inform Risk Allocation Models - Stock Traders Daily
Pulse Biosciences (NASDAQ:PLSE) Trading Up 5%Here's What Happened - MarketBeat
Net current asset value per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Pulse Biosciences drops 38% after InvestingPro’s "Overvalued" warning By Investing.com - Investing.com Australia
Pulse Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Pulse Biosciences and MD Anderson to study nPulse for thyroid cancer - MSN
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor - sharewise.com
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.70%
자본화:
|
볼륨(24시간):